CHM 2101 (CDH17 CAR T)
Status: waiting for FDA IND clearance
"Our team has been intensely dedicated in 2022 to completing all of the work necessary to move CHM 2101 into a phase 1 clinical trial as soon as possible."
- Jennifer Chow, CEO & MD, December 2022
Pfeifer,
JC and her team were involved to get 4 out of 6 CD19 CAR-T to the patients, imagine they can do it again with CD17 CAR-T.
The potential is enormous but market will be unlikely to act until safety and efficacy is demonstrated. But by then the sp won't be sub 10c anymore.
GLTA
Ann: 1st patient dosed in CHM 0201 Vactosertib trial, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $20.21K | 5.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2213046 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13563373 | 20 |
View Market Depth
| Last trade - 15.01pm 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |